Conserved Protein Domain Family
STKc_MEKK3_like

?
cd06625: STKc_MEKK3_like (this model, PSSM-Id:132956 is obsolete and has been replaced by 270795)
Catalytic domain of MAP/ERK kinase kinase 3-like Protein Serine/Threonine Kinases
Serine/threonine kinases (STKs), MAP/ERK kinase kinase 3 (MEKK3)-like subfamily, catalytic (c) domain. STKs catalyze the transfer of the gamma-phosphoryl group from ATP to serine/threonine residues on protein substrates. The MEKK3-like subfamily is part of a larger superfamily that includes the catalytic domains of other protein STKs, protein tyrosine kinases, RIO kinases, aminoglycoside phosphotransferase, choline kinase, and phosphoinositide 3-kinase. This subfamily is composed of MEKK3, MEKK2, and related proteins, all containing an N-terminal PB1 domain, which mediates oligomerization, and a C-terminal catalytic domain. MEKK2 and MEKK3 are mitogen-activated protein kinase (MAPK) kinase kinases (MAPKKKs or MKKKs or MAP3Ks), proteins that phosphorylate and activate MAPK kinases (MAPKKs or MKKs or MAP2Ks), which in turn phosphorylate and activate MAPKs during signaling cascades that are important in mediating cellular responses to extracellular signals. MEKK2 and MEKK3 activate MEK5 (also called MKK5), which activates extracellular signal-regulated kinase 5 (ERK5). The ERK5 cascade plays roles in promoting cell proliferation, differentiation, neuronal survival, and neuroprotection. MEKK3 plays an essential role in embryonic angiogenesis and early heart development. MEKK2 and MEKK3 can also activate the MAPKs, c-Jun N-terminal kinase (JNK) and p38, through their respective MAPKKs.
Statistics
?
PSSM-Id: 132956
View PSSM: cd06625
Aligned: 6 rows
Threshold Bit Score: 502.031
Threshold Setting Gi: 170576720
Created: 21-Aug-2006
Updated: 17-Jan-2013
Structure
?
Aligned Rows:
 
Feature 1:active site [active site]
Evidence:
  • Comment:The active site is composed of the ATP binding site and the substrate binding site. The substrate binding site is based on the binding of human PAK4 to a consensus peptide.

Sequence Alignment
?
Format: Row Display: Color Bits: Type Selection:
                         10        20        30        40        50        60        70        80
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                 #####   #            # #                                 #             
gi 160332306 359 PINWRRGKLLGQGAFGRVYLCYDVDTGRELASKQVQFDPDspetsKEVSALECEIQLLKNLqHERIVQYYGCLRDraekt 438
gi 62297871  353 PTNWRLGKLLGQGAFGRVYLCYDVDTGRELAVKQVQFNPEspetsKEVNALECEIQLLKNLlHERIVQYYGCLRDpqekt 432
gi 115943016 122 PTNWQRGKLLGQGAFGVVYVCYDADTGRELAVKQVPTENSntdarKEVQSLKQEIELLRNLqHPRIVQYFGCLEEng--t 199
gi 156385107   1 PNNWRKGKLLGAGAFGQVYMCHDLDTGRELAVKQIETGQLnsstkNEVKALEGEIEFMKAFrNERIVQYYGIETDdl--h 78
gi 53128199  354 PVNWRLGKLLGRGAFGEVYLCYDADTGRELSVKQVPFDPDsqetsKEVNALECEIQLLKTLrHDRIVQYYGCLRDpeerk 433
gi 170576720 219 PTNWKQGKCIGSGAFGKVYVCVDVDTGKEVALKRFNICRNdkhlkNHINQLENEINLLSTIqHNRIVQYLGAQQIde--s 296
                         90       100       110       120       130       140       150       160
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1            #### ###  #                                   # #### #         ### #        
gi 160332306 439 LTIFMEYMpGGSVKDQLKAYGaLTESVTRKYTRQILEGMSYLHsNMIVHRDIKGANILRDsaGNVKLGDFGASKRLQTIC 518
gi 62297871  433 LSIFMELSpGGSIKDQLKAYGaLTENVTRKYTRQILEGVHYLHsNMIVHRDIKGANILRDstGNIKLGDFGASKRLQTIC 512
gi 115943016 200 LSIFMEFMsGGSVKDELRLYGpLTDTVTRKYTRQILEGTAYLHdHHIVHRDIKGANVLRSs-GNVKLADFGASTRLQTIH 278
gi 156385107  79 IYIFMEYLpGGSIHEHIKQHGaLNESLTRKYSRQILEGILYLHtNRIVHRDIKGANILRDlyGNVKLADFGASKRLQTIR 158
gi 53128199  434 LSIFVEYMpGGSIKDQLKAYGaLTENVTRKYTRQILQGVFYLHsNMIVHRDIKGANILRDsaGNVKLGDFGASKRIQTIC 513
gi 170576720 297 ICIFIEYMtGGSVKDYIATYGcLSNTVAGKYTYQILHGLEYLHrNEIIHRDIKPANILRDsnGNVKIGDFGSAKRLQAIC 376
                        170       180       190       200       210       220       230       240
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....|
Feature 1                #### #                           #        #                             
gi 160332306 519 MSGTgmRSVTGTPYWMSPEVISGEg-yGRKADVWSLGCTVVEMLTeKPPWAEYEAMAAIFKIAtqPTNPQLPSHisEHGR 597
gi 62297871  513 LSGTgmKSVTGTPYWMSPEVISGEg-yGRKADIWSVACTVVEMLTeKPPWAEFEAMAAIFKIAtqPTNPKLPPHvsDYTR 591
gi 115943016 279 SHITgmKTVTGTPYWMSPEIINGEg-yGRRADVWSIGCTVVEMLTtKPPWADYEAMAAIFKIAtkETEPVLPQSvsQDAR 357
gi 156385107 159 SKTGf-RSVHGTPYWMAPEVINGEg-yGRKADVWSVGCTVVEMLTtKPPWADFEPMAALFKIAtqPTEPELPSDlsVDAV 236
gi 53128199  514 MSGTgiKSVTGTPYWMSPEVISGEg-yGRKADVWSVACTVVEMLTeKPPWAEFEAMAAIFKIAtqPTNPQLPDGvsSSCR 592
gi 170576720 377 CQQT--SPFIGTPNYMAPEVVLGHtrhGRKADIWSVGCTLVEMLTaKPPWNNLEPMAIIFNIAkhNPTYQLPIEvdPILS 454
                        250       260
                 ....*....|....*....|....*.
Feature 1                                  
gi 160332306 598 DFLRRIFVE-ARQRPSAEELLTHHFA 622
gi 62297871  592 DFLKRIFVE-AKLRPSAEELLRHMFV 616
gi 115943016 358 NFLTLCFKKiLADRPSAAELLRHNFV 383
gi 156385107 237 EFVRSTLRMnSKSRPSADELLRFSFV 262
gi 53128199  593 NFLKQIFVE-EKRRPTAEDLLRHPFV 617
gi 170576720 455 YLISITFERnVDKRPSALQLLNNFDF 480

| Disclaimer | Privacy statement | Accessibility |
NCBI Home NCBI Search NCBI SiteMap